Pruritus – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Pruritus – Pipeline Review, H1 2017’, provides an overview of the Pruritus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pruritus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pruritus and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Pruritus

The report reviews pipeline therapeutics for Pruritus by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Pruritus therapeutics and enlists all their major and minor projects

The report assesses Pruritus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Pruritus

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Pruritus

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Pruritus pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Albireo Pharma Inc

Allergan Plc

Alveonix AG

Amorepacific Corp

Asana BioSciences LLC

Cara Therapeutics Inc

Chugai Pharmaceutical Co Ltd

ELORAC Inc

GlaxoSmithKline Plc

Hydra Biosciences Inc

J Uriach Y Compania SA

NeuroCycle Therapeutics GmbH

Nippon Shinyaku Co Ltd

Patagonia Pharmaceuticals LLC

Patara Pharma Inc

Phosphagenics Ltd

RDD Pharma Ltd

Sanwa Kagaku Kenkyusho Co Ltd

Shionogi & Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Teikoku Pharma USA Inc

Tioga Pharmaceuticals Inc

Toray Industries Inc

Trevi Therapeutics Inc

Vanda Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pruritus - Overview

Pruritus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pruritus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pruritus - Companies Involved in Therapeutics Development

Albireo Pharma Inc

Allergan Plc

Alveonix AG

Amorepacific Corp

Asana BioSciences LLC

Cara Therapeutics Inc

Chugai Pharmaceutical Co Ltd

ELORAC Inc

GlaxoSmithKline Plc

Hydra Biosciences Inc

J Uriach Y Compania SA

NeuroCycle Therapeutics GmbH

Nippon Shinyaku Co Ltd

Patagonia Pharmaceuticals LLC

Patara Pharma Inc

Phosphagenics Ltd

RDD Pharma Ltd

Sanwa Kagaku Kenkyusho Co Ltd

Shionogi & Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Teikoku Pharma USA Inc

Tioga Pharmaceuticals Inc

Toray Industries Inc

Trevi Therapeutics Inc

Vanda Pharmaceuticals Inc

Pruritus - Drug Profiles

A-4250 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

asimadoline - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASN-008 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ax-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cromolyn sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

difelikefalin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2330672 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalbuphine hydrochloride ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalfurafine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naloxone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCT-10004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nemolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NS-141 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PATN-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PR-38 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RDD-1609 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rupatadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

serlopitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1405 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize KOR1 for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize CB2 for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Mas-Related G-Protein Coupled Receptor for Pruritus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize TRPV3 for Pruritus, Psoriasis and Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-120 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPU-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tradipitant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pruritus - Dormant Projects

Pruritus - Discontinued Products

Pruritus - Product Development Milestones

Featured News & Press Releases

Jan 06, 2017: Menlo Therapeutics Starts Enrollment in Two Phase 2 Studies for Pruritus Associated with Atopic Dermatitis and Pruritus Following Burn Injury

Jan 05, 2017: Menlo Therapeutics Recruits Experienced Management Team and Board Leadership to Accelerate Development of Serlopitant for Treatment of Pruritus

Jun 09, 2016: Cara Therapeutics to Present Preclinical Data at June Medical Meetings

Feb 18, 2016: Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine 32nd Annual Meeting

Oct 26, 2015: Cara Therapeutics to Present at 2nd Human Abuse Liability & Abuse-Deterrent Formulations Conference

Sep 09, 2015: Cara Therapeutics Initiates Phase 3 Program for I.V. CR845 in Acute Postoperative Pain

Jun 11, 2015: Tioga Pharmaceuticals Announces Initiation of Phase 2 Clinical Study of Asimadoline in Patients with Pruritus Associated with Atopic Dermatitis

May 12, 2015: Cara Therapeutics provides update on its Phase 3 Program for I.V. CR845

Apr 15, 2015: Cara Therapeutics to Present at 3rd Conference on the Therapeutic Potential of Kappa Opioids

Mar 19, 2015: Creabilis’ CT327 Phase 2b Data Published in Acta Dermato-Venereologica, Strengthens Scientific Advisory Board

Mar 04, 2015: Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis

Mar 03, 2015: Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES

2.5 µg and Notice Regarding Promotion Tie-up

Jan 12, 2015: Creabilis Receives Positive Feedback on CT327 from US FDA, Providing Clear Path to Registration

Dec 17, 2014: Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients

Dec 17, 2014: Velocity Pharmaceutical Development and Tigercat Pharma Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pruritus, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Pruritus – Pipeline by Albireo Pharma Inc, H1 2017

Pruritus – Pipeline by Allergan Plc, H1 2017

Pruritus – Pipeline by Alveonix AG, H1 2017

Pruritus – Pipeline by Amorepacific Corp, H1 2017

Pruritus – Pipeline by Asana BioSciences LLC, H1 2017

Pruritus – Pipeline by Cara Therapeutics Inc, H1 2017

Pruritus – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Pruritus – Pipeline by ELORAC Inc, H1 2017

Pruritus – Pipeline by GlaxoSmithKline Plc, H1 2017

Pruritus – Pipeline by Hydra Biosciences Inc, H1 2017

Pruritus – Pipeline by J Uriach Y Compania SA, H1 2017

Pruritus – Pipeline by NeuroCycle Therapeutics GmbH, H1 2017

Pruritus – Pipeline by Nippon Shinyaku Co Ltd, H1 2017

Pruritus – Pipeline by Patagonia Pharmaceuticals LLC, H1 2017

Pruritus – Pipeline by Patara Pharma Inc, H1 2017

Pruritus – Pipeline by Phosphagenics Ltd, H1 2017

Pruritus – Pipeline by RDD Pharma Ltd, H1 2017

Pruritus – Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017

Pruritus – Pipeline by Shionogi & Co Ltd, H1 2017

Pruritus – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Pruritus – Pipeline by Teikoku Pharma USA Inc, H1 2017

Pruritus – Pipeline by Tioga Pharmaceuticals Inc, H1 2017

Pruritus – Pipeline by Toray Industries Inc, H1 2017

Pruritus – Pipeline by Trevi Therapeutics Inc, H1 2017

Pruritus – Pipeline by Vanda Pharmaceuticals Inc, H1 2017

Pruritus – Dormant Projects, H1 2017

Pruritus – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Pruritus, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports